Paper 96 - PERSONALIZED CTDNA ANALYSIS IS ASSOCIATED WITH OUTCOMES AFTER PREOPERATIVE RADIOTHERAPY WITH OR WITHOUT PEMBROLIZUMAB FOR STAGE 3 SOFT TISSUE SARCOMAS ON SU2C-SARC032

Author(s)

• 

  Everett J. Moding, MD, PhD (he/him/his)

  Assistant Professor
  Stanford University
  Stanford, California, United States

  Slides

Co-Author(s)

• AS

  Ajay Subramanian, BS

  Stanford University
  Stanford, California, United States
• NN

  Neda Nernat-Gorgani, BS

  Stanford Unviersity
  Palo Alto, California, United States
• SN

  Serey Nouth, BS

  Stanford University
  Palo Alto, California, United States
• CJ

  Claire Johns, MD

  Stanford University
  Stanford, California, United States
• TS

  Timothy Sears, BS

  Stanford University
  Stanford, California, United States
• KB

  Karla V. Ballman, PhD

  Professor
  Mayo Clinic
  Rochester, Minnesota, United States
• RH

  Rachel S. Heise, MS

  Weill Cornell Medicine
  New York, New York, United States
• 

  Angela M. Hong, MBBS, MMed, PhD

  Radiation Oncologist
  Royal Prince Alfred Hospital
  Camperdown, New South Wales, Australia
• KW

  Kent J. Weinhold, PhD

  Duke Cancer Institute
  Durham, North Carolina, United States
• Mv

  Matt van de Rijn, MD, PhD

  SABINE KOHLER, MD, PROFESSOR OF PATHOLOGY
  Stanford University
  Stanford, California, United States
• BB

  Brian Brigman, MD

  Dr
  Duke University Hospital
  Durham, North Carolina, United States
• RR

  Richard F. Riedel, MD

  Duke Cancer Institute
  Durham, North Carolina, United States
• YM

  Yvonne M. Mowery, MD, PhD

  UPMC Hillman Cancer Center
  Pittsburgh, Pennsylvania, United States
• 

  David G. Kirsch, MD, PhD

  Senior Scientist
  Princess Margaret Cancer Centre
  Toronto, Ontario, Canada